Table 2 Bivariate and multivariate logistic regression of risk factors for colistin methanesulfonate-associated nephrotoxicity

Age (years)^a

57.48 (±24.01)

61.53 (±22.44)

44.56 (±24.99)

0.013

0.98 (0.96–1.04)

0.494

Body weight (kg)^a

73.67 (±21.33)

72.78 (±18.90)

76.50 (±28.26)

0.547

-

-

Male gender^b

45 (67.2%)

33(76.1%)

12 (75.0%)

0.55

-

-

Charlson Co-morbidity Score^a

2.88 (±2.39)

2.86 (±2.14)

2.94 (±3.15)

0.914

-

-

Diabetes mellitus^b

29 (43.2%)

25 (49.0%)

4 (25.0%)

0.15

0.52 (0.06–4.87)

0.568

Baseline CrCl (mL/min)^a

133.60 (±92.54)

126.02 (±85.57)

157.94 (±111.52)

0.23

0.99 (0.98–4.87)

0.108

Baseline serum albumin (mg/L)^a

28.65 (±4.45)

27.86 (±4.19)

31.19 (±4.48)

0.008

0.72 (0.57–0.93)

0.010

Intensive care unit care^b

21 (31.3%)

13 (25.5%)

8 (50.0%)

0.12

16.38 (1.37–195.55)

0.027

Receipt of CMS Loading dose

52 (77.6%)

39 (76.5%)

13 (81.3%)

1.0

-

-

CMS Dose (mU/kg/day)^a

0.11 (±0.04)

0.11 (±0.04)

0.10 (±0.04)

0.48

-

-

Cumulative CMS dose (mU)^a

101.21 (±47.37)

106.47 (±45.91

84.44 (±49.56)

0.105

1.00 (1.00–1.00)

0.133

Duration of CMS therapy (days)^a

13.76 (±6.77)

14.16 (±5.54)

12.50 (±9.86)

0.397

0.96 (0.83–1.11)

0.555

Number of concomitant nephrotoxic agents^a

0.71 (±0.62)

0.76 (±0.65)

0.56 (±0.51)

0.26

2.37 (0.50–11.19)

0.277

Concomitant vancomycin therapy^b

33 (49.3%)

24 (47.1%)

9 (56.3%)

0.576

-

-

Concomitant furosemide therapy^b

11 (16.4%)

8 (15.7%)

3 (18.75%)

0.715

-

-

Concomitant aminoglycoside therapy^b

3 (4.47%)

2 (3.92%)

1 (6.25%)

0.559

-

-

Concomitant NSAID^b

2 (2.98%)

2 (3.92%)

0 (0.0%)

1.00

-

-

Concomitant radiological contrast^b

1 (1.49%)

1 (1.96%)

0 (0.0%)

1.00

-

-

Concomitant amphotericin b therapy^b

0 (0.0%)

0 (0.0%)

0 (0.0%)

1.00

-

-